Lista de obras - Rikke Fredslund Andersen

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

artículo científico publicado en 2006

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy

artículo científico publicado en 2017

Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

artículo científico

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.

artículo científico publicado en 2014

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

artículo científico publicado en 2014

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer

artículo científico publicado en 2019

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer

artículo científico publicado en 2015

Circulating microRNAs as biomarkers of adult Crohn's disease.

artículo científico publicado en 2015

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

artículo científico publicado en 2015

Controls to validate plasma samples for cell free DNA quantification.

artículo científico publicado en 2015

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).

artículo científico publicado en 2011

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

scientific article published on 09 January 2019

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.

artículo científico publicado en 2009

Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study

Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons

artículo científico publicado en 2014

Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. ⬇️

artículo científico publicado en 2016

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer

artículo científico publicado en 2013

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

artículo científico publicado en 2013

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

artículo científico publicado en 2016

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

artículo científico publicado en 2013

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

artículo científico publicado en 2018

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

artículo científico publicado en 2019

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers

artículo científico publicado en 2019

Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment

scientific article published on 24 October 2018

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.

artículo científico publicado en 2013

Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial

artículo científico publicado en 2019

Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer

scientific article published on 01 September 2012

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.

artículo científico publicado en 2014

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab

artículo científico publicado en 2017

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

scientific article published on 01 July 2008

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification.

artículo científico publicado en 2015

Quantification of microRNA in plasma using probe based TaqMan assays: is microRNA purification required?

artículo científico publicado en 2019

Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions

artículo científico publicado en 2018

Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer

artículo científico publicado en 2009

Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

artículo científico publicado en 2005

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

artículo científico publicado en 2008

Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.

artículo científico publicado en 2014

Screening for circulating RAS/RAF mutations by multiplex digital PCR.

artículo científico publicado en 2016

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

artículo científico publicado en 2013

Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer ⬇️

artículo científico publicado el 31 de julio de 2012

The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer

artículo científico publicado en 2009

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

artículo científico publicado en 2009

The influence of tissue ischemia on biomarker expression in colorectal cancer.

artículo científico publicado en 2013

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

artículo científico publicado en 2010

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer ⬇️

artículo científico publicado el 6 de diciembre de 2011

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

artículo científico publicado en 2012

The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer

artículo científico publicado en 2010

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer ⬇️

artículo científico publicado en 2017

Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses

scientific article published on 13 November 2018

Lista de obras de Rikke Fredslund Andersen

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy

Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer

Circulating microRNAs as biomarkers of adult Crohn's disease.

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

Controls to validate plasma samples for cell free DNA quantification.

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.

Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study

Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons

Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. ⬇️

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers

Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.

Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial

Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification.

Quantification of microRNA in plasma using probe based TaqMan assays: is microRNA purification required?

Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions

Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer

Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.

Screening for circulating RAS/RAF mutations by multiplex digital PCR.

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer ⬇️

The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

The influence of tissue ischemia on biomarker expression in colorectal cancer.

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer ⬇️

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer ⬇️

Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses